Follow-Up of Side Effects throughout the Entire Course of Coronavirus Vaccination
1
Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, P.O. Box 330127, Zarqa 13133, Jordan
2
Department of Pathology and Forensic Medicine, Faculty of Medicines, Hashemite University, P.O. Box 330127, Zarqa 13133, Jordan
3
Faculty of Medicine, Hashemite University, P.O. Box 330127, Zarqa 13133, Jordan
*
Author to whom correspondence should be addressed.
Vaccines 2023, 11(3), 704; https://doi.org/10.3390/vaccines11030704
Received: 30 January 2023
/
Revised: 10 March 2023
/
Accepted: 12 March 2023
/
Published: 20 March 2023
(This article belongs to the Special Issue Adverse Events of COVID-19 Vaccines)
Abstract
:Vaccines are considered the best protective means against coronavirus infection. There is increasing interest in reporting the side effects of vaccines, especially for individuals younger than 18 years old. Accordingly, this analytical cohort study aims to report on the side effects of adult and young individuals who received vaccination within 24 h, 72 h, 5 days, and 1 week through the entire course of vaccination (ECoV). A validated online survey was used to collect information. In total, 1069 individuals were completely followed. Most individuals received the Pfizer vaccine (59.6%). Most individuals had received two doses (69.4%). Very strong and statistically significant associations with side effects (p < 0.05, Phi (Φ) > 0.25) throughout the ECoV were reported for the type of vaccine and female gender. Non-smokers reported weak statistically significant associations. Fatigue and localized pain were the most commonly reported side effect, with onset within 24 h and duration of less than 72 h. The prevalence of reported side effects was statistically significantly higher among young individuals (<18 years old) than among adults (X2 (1) =7.6, p = 0.006. Phi φ = 0.11).
1. Introduction
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which mainly affects the respiratory system [1]. The first recorded case was in Wuhan, China, in December 2019 [2]. The World Health Organization (WHO) declared COVID-19 a pandemic in March 2020 [2]. Thereafter, developing a vaccine became a high priority to confront this pandemic. Pfizer-BioNTech and Oxford-AstraZeneca are nucleic acid vaccines based on messenger ribonucleic acid (mRNA) and double-stranded deoxyribonucleic acid (dsDNA), respectively [3]. Sinopharm, on the other hand, is an inactivated coronavirus vaccine [4].
In January 2021, the Jordanian ministry of health launched the national vaccination program, which was set to include all children over 12 years old in the vaccination process. The most used vaccines in Jordan are Pfizer-BioNTech, Sinopharm, and Oxford-AstraZeneca. In July 2022, more than four million adults had been vaccinated with two doses, while more than 500,000 had received three doses [5].
Despite the efficacy of COVID-19 vaccines, there are many common side effects [6,7]. The incidence may differ greatly depending on the type of given vaccine. Sinopharm has shown the mildest side effects, such as pain at the injection site, fatigue, headache, lethargy, and muscle pain. In rare situations, however, vaccine-induced immune thrombotic thrombocytopenia (VITT) has been recorded as a life-threatening side effect [8,9]. The Oxford-AstraZeneca vaccine has shown comparatively more serious side effects, which include thrombosis, Guillain–Barré syndrome, acute transverse myelitis, myocarditis, pericarditis, and glomerular disease [6].
The side effects of the Pfizer-BioNTech vaccine are most commonly mild to moderate and include muscle pain, joint pain, itching, lymph node swelling, nausea, dyspnea, and diarrhea, with a minor incidence of life-threatening side effects such as angioedema, pancarditis, Bell’s palsy, and anaphylactic shock [10].
Notwithstanding the fact that adolescents and children aged below 18 years mostly exhibit less severe SARS-CoV-2 infection than adults, severe symptoms have also been reported in these age groups, specifically in individuals with underlying medical comorbidities [11]. Attributable to their role in SARS-CoV-2 transmission, vaccination of adolescents and children may contribute to the development of herd immunity within societies [12,13]. The pandemic has impacted in-person learning, socialization, and ultimately, the education of school-aged children and adolescents [14,15].
The Food and Drug Administration expanded the emergency use authorization for the BNT162b2 (Pfizer-BioNTech) vaccine on 10 May 2021, including individuals 12 years of age or older [16], which made it the only vaccine authorized for use in adolescents younger than 16 years of age. In a recent study titled “Safety, Immunogenicity, and Efficacy of the BNT162b2 COVID-19 Vaccine in Adolescents”, BNT162b2 was found to have high efficacy against SARS-CoV-2 in participants aged 12 to 15 years and elicit a more significant immune response with a favorable safety profile, mostly ephemeral mild-to-moderate side effects (primarily, injection site pain, fatigue, and headache) [17]. Severe adverse events following the administration of BNT162b2, including myocarditis, are scarcely reported in adolescents [18].
Most of the adverse effects identified in adults are reported as mild-to-moderate events for which no in-patient treatment is required [19]. Severe adverse events have been outlined, most requiring hospitalization and possibly life-threatening, including venous thromboembolism, stroke, myocardial infarction, pulmonary embolism, myocarditis, and pericarditis [17,20,21,22,23].
There is still a need to explore side effects reported for individuals who have received vaccines along the entire course of vaccination (ECoV), including those who are less than 18 years old. The present research was therefore designed as an analytical cohort study to report the side effects of adult and young individuals who received vaccination within 24 h, 72 h, 5 days, and 1 week throughout the ECoV. We then explored the associations and measured the nominal-by-nominal relationship between independent variables and the reported side effects during the ECoV.
2. Materials and Methods
A longitudinal analytical cohort study. An online platform was developed to collect data, with six well-trained medical students collecting data from the vaccination center at Hashemite University and another two centers from 15 November 2021 to 30 August 2022. Data were collected for those who agreed to take part in the study face-to-face while visiting the center and then by phone call using their registered mobile phone numbers 1 day, 3 days, 5 days, and 1 week after each injection. Accordingly, those who received a single dose of the vaccine were contacted after injection. Those who received two doses were contacted after the first and second shots of the vaccine. Those who received three doses were contacted after the first, second, and third shots. Those who received heterogeneous vaccinations were excluded from the study.
The Google Sheets platform was used to develop a spreadsheet to collect data from participants, with a specific ID assigned for each. In the process of designing the questions, the research team shared the draft with eight experts, who provided comments and feedbackthat were considered by the research team. Only items that had an accepted content validity ratio (CVR) were used, i.e., with the assessment of eight experts, only items with Lawshe’s content validity ratio (CVR) > 0.741, p < 0.05 were considered [24].
The questionnaire had the following sections: (1) demographics; (2) comorbidities, allergies, and medication; (3) the profile of side effects (symptoms of the side effect, onset, duration, severity—impact on daily life, data for which were collected after each injection throughout the ECoV). The categories for side effects [19] were classified as mild (i.e., does not interfere with daily activity such as general tasks, mood, mobility, and normal work), moderate (i.e., interferes with daily activity, but no hospitalization), or severe (cases involving hospitalization).
Before enrollment, participants received a full description of the study, they were informed that their vaccination number would be recorded for follow-up and would be used as their ID number. No specific personal data were collected, and data would be treated as confidential in all cases. Subjects were also informed that participation is totally voluntary, and they could withdraw at any stage without the need to clarify reasons for their request. The study protocol was approved by the institutional review board (IRB) committee at Hashemite University (No. 13/1/2021/2022).
In Jordan, almost 3.53 million people were fully vaccinated by Nov 2021 [5,25]. Based on this number, a sample size of minimum of 385 participants was considered representative as recommended by Taherdoost [26] and carried out by the sample size calculator [27] considering a confidence level of 95% and a margin of error of 5%.
Data were coded and transferred to SPSS for Windows, version 25, for statistical analysis (SPSS Inc., Chicago, IL, USA). For data analysis, descriptive analysis was first conducted to present participant characteristics. The chi-squared test (X2) for association was used (Fisher’s exact test was used in cases where the expected count was less than 5). To measure the strength of the association of a nominal-by-nominal relationship (which is a measure of effect size), the Phi (Φ) coefficient factor was also calculated and illustrated, with a strength of association value of 1 indicating complete association, “0” indicating no association, >0.25 indicating a very strong relationship, >0.15 indicating a strong relationship, >0.1 indicating a moderate relationship, and >0.05 indicating a weak relationship [28]. The degrees of freedom for the chi-square between practices were illustrated using the formula df = (r − 1)(c − 1), where r is the number of categories within the demographic variable and c is the number of options related to item options. For all tests in the present study, a p-value of <0.05 is considered to indicate a statistically significant difference [29].
3. Results
Results are presented within the following sections: Section 3.1 Descriptive results for the participant and comorbidities. Section 3.2 Descriptive for side effect types, onset, duration, and impact. Section 3.3 Analysis of the relationship and association within and between variables.
3.1. Descriptive Results
3.1.1. Descriptive Results for Individuals
Table 1 shows the characteristics of the 1069 individuals who were enrolled in our study. In all, 542 (50.7%) were male and 527 (49.3%) were female. The majority were young, between 18 and 40 years old (63.7%), living in Amman (701, 65.6%), and non-smokers (874, 81.8%). Regarding the highest educational level, 685 (64.1%) of participants held a bachelor’s degree, 104 (9.7%) held a diploma degree, 49 (4.6%) held a master’s/PhD degree, 52 (4.9%) had attended primary school, and 179 (16.7%) had attended secondary school. Most participants were non-HCWs (662 or 62% compared with 406 or 38% who worked in healthcare). The majority of participants received the Pfizer-BioNTech vaccine (637, 59.6%), followed by Sinopharm (387, 36.2%) and AstraZeneca (45, 4.2%).
3.1.2. Description of Comorbidities and Other Variables (Allergies and Medications)
Table 2 shows that spring (seasonal) allergies were the most common, affecting 25.26% of total participants, with the least common allergy found to be walnut fruit allergy. Among chronic diseases, hypertension was the most common, followed by diabetes and coronary artery disease, while only eight individuals reported liver disease and neurological disease. The most common medication type was painkiller (NSAID and others), followed by hypertension and anti-coagulant.
3.2. Descriptive for Side Effects Types, Onset, Duration, and Impact
3.2.1. Type of Side Effects and Number of Doses
Table 3 shows the incidence of side effects according to the number of doses that the individual received. The majority of individuals suffer from fatigue, fever, headache, localized pain, and myalgia. Other individuals suffered from arthralgia, chills, and localized redness. A small minority of individuals suffered from side effects such as dizziness, diarrhea, cough, rhinorrhea, nasal congestion, sneezing, shortness of breath, nausea, vomiting, sore throat, facial swelling, ageusia, anosmia, and neurological symptoms.
3.2.2. Severity of Reported Side Effects
Most individuals suffer side effects with mild impact, with less than 3% requiring hospitalization for complications (Figure 1).
3.2.3. Side Effects and 1-Week Follow-Up
The majority of individuals suffered from side effects within 24 h of vaccination. Other individuals suffered from side effects 1–3 days after vaccination. A small minority of individuals suffered from side effects later than 1 week after vaccination. As seen in Table 4, almost 14% of those who received three doses suffered from minor side effects for periods longer than 1 week.
3.3. Analysis of the Relationship, Associations within and between Variables
Table 5 shows the frequency of reported side effects and their association with different variables after each injection of vaccine throughout the entire course of vaccination.
3.3.1. Individuals Who Received a Single Dose
The profiles of side effects show no statistically significant differences across all tested variables (gender, age, smoking status, and vaccines).
3.3.2. Individuals Who Received Two Doses
After the first shot for those who received two doses of vaccines, individuals receiving the Pfizer vaccine reported a statistically significant higher percentage of side effects compared with those receiving Sinopharm and AstraZeneca vaccines (64.7% vs. 28.8% and 6.5%, respectively, X2 (4) = 50.8, p < 0.001), and the association was very strong (Phi φ = 0.26). Females reported statistically significant side effects more than males (57.6% vs. 42.2%, X2 (1) = 164.5, p < 0.001, and the association was very strong (Phi φ =0.53). Non-smokers reported statistically significant side effects compared with smokers (X2 (1) = 4.2, p = 0.042); however, the association strength was weak (Phi φ = 0.08). In line with the results from the first shot, variables such as gender, smoking, and the type of vaccine maintained their statistically significant association with the side effect profile. However, at this stage, a new variable “age’’ was also reported to be statistically significantly associated. Patients receiving the Pfizer vaccine reported a statistically significant higher percentage of side effects compared with Sinopharm and AstraZeneca (70.7% vs. 24.3% and 5.1%, respectively, X2 (4) = 54.7, p < 0.001), and the association was very strong (Phi φ =0.27). Significantly more females than males reported side effects (58% vs. 42%, X2 (1) =21.3, p < 0.001, and the association was very strong (Phi φ = 0.38). Non-smokers reported a higher percentage of side effects, but the association was weak (Phi φ = 0.08). After the second shot for those who received two doses of vaccines, the prevalence of reported side effects versus no side effects among young individuals (<18 years old) was higher than for the elderly (>18 years), and this difference was statistically significant (X2 (1) =7.6, p = 0.006, and the association strength was moderate (Phi φ = 0.11.)
3.3.3. Individuals Who Received Three Doses of Vaccine
After the first shot for those who received three doses of vaccines, a statistically significant higher percentage of side effects was reported for patients receiving the Pfizer rather than Sinopharm and AstraZeneca vaccines (76.9% vs. 15.7% and 7.4%, respectively, X2 (4) = 16.2, p = 0.002), and the association was strong (Phi φ =0.25). Significantly more females than males reported side effects (63.6% vs. 36.4%, X2 (1) = 4, p = 0.045). However, the strength of the association was weaker than that reported for those who had received two doses (Phi φ = 0.13 vs. Phi φ = 53).
4. Discussion
The present study showed that after the first shot of those who received two doses of vaccines, individuals that received the Pfizer vaccine reported a statistically significant higher percentage of side effects compared with those receiving Sinopharm and AstraZeneca vaccines. This finding contradicts the conclusion of two studies that were conducted to compare different types of vaccines against COVID-19, which found more side effects resulting from the AstraZeneca vaccine compared with Pfizer and Sinopharm vaccines [30,31]. This can be attributed to the lower number of participants who received the AstraZeneca vaccine in our study.
Similar to the findings of several published studies in Jordan or worldwide [8,31,32,33,34,35,36,37], the most commonly reported side effects following COVID-19 vaccination, regardless of the type of vaccine, are fatigue, fever, headache, localized pain, and myalgia. In the present study, the severity of side effects was assessed by the questionnaire. Most responders (nearly 90%) reported a mild to moderate impact on life, while less than 3% required hospitalization. This is in agreement with similar studies conducted in the same region [8,32,33,38]. Moreover, our study showed that the majority of vaccine recipients had vaccination side effects for less than 3 days’ duration, which is in line with the results of a study conducted in India illustrating that vaccination side effects tend to resolve within 48 hours of vaccine administration [39].
There are many studies that demonstrate the variety of vaccine side effects based on gender [40]. The present study shows that females experienced more side effects compared with males [40,41], and the variation between males and females is attributed to sex hormones, including estrogen, progesterone, and testosterone, which can bind to the surface of immune cells and influence how they work. Exposure to estrogen causes immune cells to produce more antibodies in response to the vaccine in general [42]. Some studies reported no difference between males and females [43]. Nevertheless, there are others showing that more males suffer from side effects than females [44]. Our results support those studies and scientific explanations reporting females having a higher sensitivity to side effects. In the present study, differences in side effect profiles based on gender had diminished in those who received three doses of vaccines.
The present results highlight that non-smokers are more susceptible to experiencing more significant side effects in comparison with smokers. This finding is in agreement with the results of studies by Abukhalil et al. and Hatmal et al. [45,46]. However, in the study of Al-Hanawi et al., a higher prevalence of moderate adverse effects among smokers in contrast to non-smokers was demonstrated [47]. Historically, the influence of smoking on vaccination has been studied. A study conducted in the Netherlands showed a greater response of antibodies toward the influenza vaccine in smokers compared with non-smokers, which might indicate a modulatory role of smoking over the immune system that in turn affects the body’s response toward vaccination [48].
The present study evaluated the implications of the Pfizer-BioNTech vaccine in participants aged <18 years old. After the second shot of those who received two doses of the vaccine, the prevalence of reported side effects versus no side effects was higher among young individuals (<18 years old) than among adults (>18 years old). Such results are similar to those reported in other studies [17,19]. This might be explained by increased reactogenicity and increased vaccine-induced immunogenicity, which may lead to more intense inflammatory responses in younger people [19,49]. Most side effects described after the second dose of the Pfizer-BioNTech vaccine in young participants (<18 years old) are transient mild-to-moderate side effects (predominantly injection site pain, fatigue, headache, fever, and myalgia) as confirmed by Robert and colleagues [17].
Similar to the findings of our study, there is increasing evidence confirming that females and younger people tend to report more side effects from COVID-19 vaccines [50]. Nevertheless, nocebo effects [51,52] of COVID-19 vaccines should be considered [53,54]. The incidence of nocebo response to COVID-19 vaccines was reported to be high (16.4%) in a recent meta-analysis [55]. Earlier systematic reviews found little evidence for a gender effect [56], with females observed to be more vulnerable to nocebo effects [57]. While nocebo effects are driven more by misinformation (verbal manipulation) in males, they are found to be driven by conditioning and previous experience in females [58]. This lagged effect is further documented by Hoffman and colleagues [59], who reported that COVID-19 vaccine side effects decreased across waves for males but increased for females. Accordingly, the association between wave one and wave two side effects (wave one following a second Pfizer dose, wave two after their booster) was more robust in females. They also reported no association across the waves between side effects and age. Such results are strongly linked with the findings of the present study.
4.1. Strengths
This study has numerous strengths. It follows the side effect profile after each vaccine injection despite the number of doses, and information is then presented for each injection and dose of vaccine. Such presentation went hand-in-hand with related statistical analysis. For the present study, the recruited participants amounted to a very robust sample size, especially for individuals younger than 18 years who received the vaccination.
4.2. Limitations
The present study has some limitations, for example, we could not access the hospital admissions after vaccination to validate the causality association between vaccine and admission. Information in the present study is mainly dependent on participants’ self-assessment, which may differ from one person to another. In addition to the standard bias are the participants’ recall bias [60] and the Hawthorne effect [61].
5. Conclusions
The profile of side effects in terms of prevalence, severity, onset, and duration of action was almost constant across the entire course of vaccination. Most side effects, regardless of the type of vaccine, were mild and disappeared 3 days after injections. One week after vaccination was the period corresponding to being totally free of side effects. Mainly females and, to a lesser extent, non-smokers were more sensitive to side effects and reported consistent claims across the entire course of vaccination. In the present study, the Pfizer-BioNTech vaccine was the most used vaccine, followed by Sinopharm and AstraZeneca. Individuals younger than 18 years of age reported a higher prevalence of side effects compared with older individuals.
Author Contributions
Conceptualization, H.A.H., A.A., M.A., L.S., A.D., H.A.; methodology, M.O., G.N.A.-J.; software, M.O., L.S., H.A., M.A.; validation, G.N.A.-J., A.A., H.A.H., A.D.; formal analysis, M.O., M.A., A.A.; investigation, G.N.A.-J., L.S., H.A.H., A.D.; resources, H.A.; data curation; M.O., A.D., H.A.H.; writing—original draft preparation, A.A., M.A., L.S.; writing—review and editing, M.O., G.N.A.-J., A.A., H.A.H.; visualization, M.A., A.D.; supervision, M.O., G.N.A.-J.; project administration, M.O., G.N.A.-J.; funding acquisition, None. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study protocol was approved by the institutional review board (IRB) committee at Hashemite University (No. 13/1/2021/2022).
Informed Consent Statement
Written informed consent has been obtained from individuals to publish this paper.
Data Availability Statement
The data presented in this study are available on request from the corresponding author.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Li, Y.-D.; Chi, W.-Y.; Su, J.-H.; Ferrall, L.; Hung, C.-F.; Wu, T.-C. Coronavirus vaccine development: From SARS and MERS to COVID-19. J. Biomed. Sci. 2020, 27, 104. [Google Scholar] [CrossRef] [PubMed]
- Habas, K.; Nganwuchu, C.; Shahzad, F.; Gopalan, R.; Haque, M.; Rahman, S.; Majumder, A.A.; Nasim, T. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev. Anti-Infect. Ther. 2020, 18, 1201–1211. [Google Scholar] [CrossRef] [PubMed]
- Mahase, E. How the Oxford-AstraZeneca covid-19 vaccine was made. BMJ 2021, 372, n86. [Google Scholar] [CrossRef]
- Wang, H.; Zhang, Y.; Huang, B.; Deng, W.; Quan, Y.; Wang, W.; Xu, W.; Zhao, Y.; Li, N.; Zhang, J.; et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell 2020, 182, 713–721.e9. [Google Scholar] [CrossRef]
- Ministry of Health Jordan. Jordanian Government Website. Corona Updat. 2022. Available online: https://corona.moh.gov.jo/en (accessed on 25 July 2022).
- Mushtaq, H.A.; Khedr, A.; Koritala, T.; Bartlett, B.N.; Jain, N.K.; Khan, S.A. A review of adverse effects of COVID-19 vaccines. Le Infez. Med. 2022, 30, 1. [Google Scholar] [CrossRef]
- Babaee, E.; Amirkafi, A.; Tehrani-Banihashemi, A.; SoleimanvandiAzar, N.; Eshrati, B.; Rampisheh, Z.; Asadi-Aliabadi, M.; Nojomi, M. Adverse effects following COVID-19 vaccination in Iran. BMC Infect. Dis. 2022, 22, 476. [Google Scholar] [CrossRef]
- Saeed, B.Q.; Al-Shahrabi, R.; Alhaj, S.S.; Alkokhardi, Z.M.; Adrees, A.O. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int. J. Infect. Dis. 2021, 111, 219–226. [Google Scholar] [CrossRef] [PubMed]
- Hosseinzadeh, R.; Barary, M.; Mehdinezhad, H.; Sio, T.T.; Langer, F.; Khosravi, S. Thrombotic thrombocytopenia after Sinopharm BBIBP-CorV COVID-19 vaccination. Res. Pract. Thromb. Haemost. 2022, 6, e12750. [Google Scholar] [CrossRef]
- Dighriri, I.M.; Alhusayni, K.M.; Mobarki, A.Y.; Aljerary, I.S.; Alqurashi, K.A.; Aljuaid, F.A.; Alamri, K.A.; Mutwalli, A.A.; Maashi, N.A.; Aljohani, A.M.; et al. Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review. Cureus 2022, 14, e23526. [Google Scholar] [CrossRef]
- Tsabouri, S.; Makis, A.; Kosmeri, C.; Siomou, E. Risk Factors for Severity in Children with Coronavirus Disease 2019. Pediatr. Clin. North Am. 2020, 68, 321–338. [Google Scholar] [CrossRef]
- Rumain, B.; Schneiderman, M.; Geliebter, A. Prevalence of COVID-19 in adolescents and youth compared with older adults in states experiencing surges. PLoS ONE 2021, 16, e0242587. [Google Scholar] [CrossRef] [PubMed]
- Szablewski, C.M.; Chang, K.T.; Brown, M.M.; Chu, V.T.; Yousaf, A.R.; Anyalechi, N.; Aryee, P.A.; Kirking, H.L.; Lumsden, M.; Mayweather, E.; et al. SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp—Georgia, June 2020. MMWR. Morb. Mortal. Wkly. Rep. 2020, 69, 1023–1025. [Google Scholar] [CrossRef]
- Buonsenso, D.; Roland, D.; De Rose, C.; Vásquez-Hoyos, P.; Ramly, B.; Chakakala-Chaziya, J.N.; Munro, A.; González-Dambrauskas, S. Schools Closures During the COVID-19 Pandemic. Pediatr. Infect. Dis. J. 2021, 40, e146–e150. [Google Scholar] [CrossRef] [PubMed]
- Masonbrink, A.R.; Hurley, E. Advocating for Children During the COVID-19 School Closures. Pediatrics 2020, 146, e20201440. [Google Scholar] [CrossRef]
- Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic. Food Drug Adm. 2021. Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use (accessed on 10 May 2021).
- Frenck, R.W., Jr.; Klein, N.P.; Kitchin, N.; Gurtman, A.; Absalon, J.; Lockhart, S.; Perez, J.L.; Walter, E.B.; Senders, S.; Bailey, R.; et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N. Engl. J. Med. 2021, 385, 239–250. [Google Scholar] [CrossRef] [PubMed]
- Hause, A.M.; Gee, J.; Baggs, J.; Abara, W.E.; Marquez, P.; Thompson, D.; Su, J.R.; Licata, C.; Rosenblum, H.G.; Myers, T.R.; et al. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years. Morb. Mortal. Wkly. Rep. 2021, 70, 1053–1058. [Google Scholar] [CrossRef]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
- García-Grimshaw, M.; Ceballos-Liceaga, S.E.; Hernández-Vanegas, L.E.; Núñez, I.; Hernández-Valdivia, N.; Carrillo-García, D.A.; Michel-Chávez, A.; Galnares-Olalde, J.A.; Carbajal-Sandoval, G.; Saniger-Alba, M.D.M.; et al. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study. Clin. Immunol. 2021, 229, 108786. [Google Scholar] [CrossRef]
- Bozkurt, B.; Kamat, I.; Hotez, P.J. Myocarditis with COVID-19 mRNA Vaccines. Circulation 2021, 144, 471–484. [Google Scholar] [CrossRef]
- Matta, A.; Kunadharaju, R.; Osman, M.; Jesme, C.; McMiller, Z.; Johnson, E.M.; Matta, D.; Kallamadi, R.; Bande, D. Clinical Presentation and Outcomes of Myocarditis Post mRNA Vaccination: A Meta-Analysis and Systematic Review. Cureus 2021, 13, e19240. [Google Scholar] [CrossRef]
- Blumenthal, K.G.; Phadke, N.A.; Bates, D.W. Safety Surveillance of COVID-19 mRNA Vaccines through the Vaccine Safety Datalink. JAMA 2021, 326, 1375–1377. [Google Scholar] [CrossRef] [PubMed]
- Wilson, F.R.; Pan, W.; Schumsky, D.A. Recalculation of the Critical Values for Lawshe’s Content Validity Ratio. Meas. Evaluation Couns. Dev. 2012, 45, 197–210. [Google Scholar] [CrossRef][Green Version]
- Our Warld in Data. Coronavirus (COVID-19) Vaccinations. Vaccin. Dataset. 2021. Available online: https://ourworldindata.org/covid-vaccinations?country=JOR (accessed on 1 November 2021).
- Taherdoost, H. Determining Sample Size; How to Calculate Survey Sample Size. Int. J. Econ. Manag. Syst. 2017, 2, 236–239. [Google Scholar]
- Qualtrics. Sample Size Calculater. 2020. Available online: https://www.qualtrics.com/blog/calculating-sample-size/?fbclid=IwAR0urxilwycKuIxHio2ttEZ_yFvncrYA9BgXCJd5jQJeho2zmzfR4l3z2TU (accessed on 2 November 2021).
- Akoglu, H. User’s guide to correlation coefficients. Turk. J. Emerg. Med. 2018, 18, 91–93. [Google Scholar] [CrossRef] [PubMed]
- Cohen, J. Chi-Square Tests for Goodness of Fit and Contingency Tables. Stat Power Anal Behav. Sci. 1977, 2, 215–271. [Google Scholar] [CrossRef]
- Kim, H.-Y. Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test. Restor. Dent. Endod. 2017, 42, 152–155. [Google Scholar] [CrossRef] [PubMed]
- Wu, Q.; Dudley, M.Z.; Chen, X.; Bai, X.; Dong, K.; Zhuang, T.; Salmon, D.; Yu, H. Evaluation of the safety profile of COVID-19 vaccines: A rapid review. BMC Med. 2021, 19, 173. [Google Scholar] [CrossRef] [PubMed]
- Omeish, H.; Najadat, A.; Al-Azzam, S.; Tarabin, N.; Abu Hameed, A.; Al-Gallab, N.; Abbas, H.; Rababah, L.; Rabadi, M.; Karasneh, R.; et al. Reported COVID-19 vaccines side effects among Jordanian population: A cross sectional study. Hum. Vaccines Immunother. 2021, 18, 1981086. Available online: https://www.tandfonline.com/doi/suppl/10.1080/21645515.2021.1981086?scroll=top&role=tab (accessed on 1 November 2021). [CrossRef]
- Hatmal, M.; Al-Hatamleh, M.; Olaimat, A.; Hatmal, M.; Alhaj-Qasem, D.; Olaimat, T.; Mohamud, R. Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines 2021, 9, 556. [Google Scholar] [CrossRef]
- Ganesan, S.; Al Ketbi, L.M.B.; Al Kaabi, N.; Al Mansoori, M.; Al Maskari, N.N.; Al Shamsi, M.S.; Alderei, A.S.; El Eissaee, H.N.; Al Ketbi, R.M.; Al Shamsi, N.S.; et al. Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE—An Observational Study. Front. Public Health 2022, 10, 876336. [Google Scholar] [CrossRef]
- Almughais, E.S.; Alharbi, A.H.; Aldarwish, H.A.; Alshammari, A.F.; Alsuhaymi, R.S.; Almuaili, J.A.; Alanizy, A.M. Side-effects of COVID-19 vaccines among the Saudi population. Saudi Med. J. 2022, 43, 386–393. [Google Scholar] [CrossRef]
- Yesuf, E.A.; Riad, A.; Sofi-Mahmudi, A.; Sudhakar, M.; Mekonnen, A.; Endalkachew, S.; Mama, F.; Muhidin, S.; Ayele, B.; Yahya, M.; et al. Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study. Front. Public Health 2022, 10, 937794. [Google Scholar] [CrossRef] [PubMed]
- Menni, C.; Klaser, K.; May, A.; Polidori, L.; Capdevila, J.; Louca, P.; Sudre, C.H.; Nguyen, L.H.; Drew, D.A.; Merino, J.; et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet Infect. Dis. 2021, 21, 939–949. [Google Scholar] [CrossRef] [PubMed]
- Chapin-Bardales, J.; Gee, J.; Myers, T. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. JAMA 2021, 325, 2201–2202. [Google Scholar] [CrossRef] [PubMed]
- Omeish, H.; Najadat, A.; Al-Azzam, S.; Tarabin, N.; Abu Hameed, A.; Al-Gallab, N.; Abbas, H.; Rababah, L.; Rabadi, M.; Karasneh, R.; et al. Reported COVID-19 vaccines side effects among Jordanian population: A cross sectional study. Hum. Vaccines Immunother. 2021, 18, 1981086. [Google Scholar] [CrossRef] [PubMed]
- Kaur, R.J.; Dutta, S.; Bhardwaj, P.; Charan, J.; Dhingra, S.; Mitra, P.; Singh, K.; Yadav, D.; Sharma, P.; Misra, S. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J. Clin. Biochem. 2021, 36, 427–439. [Google Scholar] [CrossRef]
- Al-Qazaz, H.K.; Al-Obaidy, L.M.; Attash, H.M. COVID-19 vaccination, do women suffer from more side effects than men? A retrospective cross-sectional study. Pharm. Pract. 2022, 20, 2678. [Google Scholar] [CrossRef] [PubMed]
- Elnaem, M.H.; Taufek, N.H.M.; Ab Rahman, N.S.; Nazar, N.I.M.; Zin, C.S.; Nuffer, W.; Turner, C.J. COVID-19 Vaccination Attitudes, Perceptions, and Side Effect Experiences in Malaysia: Do Age, Gender, and Vaccine Type Matter? Vaccines 2021, 9, 1156. [Google Scholar] [CrossRef]
- Taneja, V. Sex Hormones Determine Immune Response. Front. Immunol. 2018, 9, 1931. [Google Scholar] [CrossRef]
- Vassallo, A.; Shajahan, S.; Harris, K.; Hallam, L.; Hockham, C.; Womersley, K.; Woodward, M.; Sheel, M. Sex and Gender in COVID-19 Vaccine Research: Substantial Evidence Gaps Remain. Front. Glob. Women’s Health 2021, 2, 761511. [Google Scholar] [CrossRef]
- Alemayehu, A.; Demissie, A.; Yusuf, M.; Abdullahi, Y.; Abdulwehab, R.; Oljira, L.; Feleke, D. COVID-19 vaccine side effect: Age and gender disparity in adverse effects following the first dose of AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia: A community-based study. SAGE Open Med. 2022, 10, 205031212211086. [Google Scholar] [CrossRef] [PubMed]
- Hatmal, M.M.; Al-Hatamleh, M.A.I.; Olaimat, A.N.; Mohamud, R.; Fawaz, M.; Kateeb, E.T.; Alkhairy, O.K.; Tayyem, R.; Lounis, M.; Al-Raee, M.; et al. Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Vaccination: A Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Post-Vaccination Adverse Effects Based on Predisposing Factors. Vaccines 2022, 10, 366. [Google Scholar] [CrossRef]
- Abukhalil, A.D.; Shatat, S.S.; Abushehadeh, R.R.; Al-Shami, N.; Naseef, H.A.; Rabba, A. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community. BMC Infect. Dis. 2023, 23, 5. [Google Scholar] [CrossRef] [PubMed]
- Al-Hanawi, M.K.; Keetile, M.; Kadasah, N.A.; Alshareef, N.; Qattan, A.M.N.; Alsharqi, O. Side Effects and Perceptions of COVID-19 Vaccination in Saudi Arabia: A Cross-Sectional Study. Front. Med. 2022, 9, 1462. [Google Scholar] [CrossRef]
- Capponi, M.; Pulvirenti, F.; Cinicola, B.L.; Brindisi, G.; Conti, M.G.; Colaiocco, G.; de Castro, G.; Guido, C.A.; Duse, M.; Midulla, F.; et al. Short-Term Side Effects and SARS-CoV-2 Infection after COVID-19 Pfizer–BioNTech Vaccine in Children Aged 5–11 Years: An Italian Real-World Study. Vaccines 2022, 10, 1056. [Google Scholar] [CrossRef] [PubMed]
- Smith, L.E.; Sim, J.; Sherman, S.M.; Amlôt, R.; Cutts, M.; Dasch, H.; Sevdalis, N.; Rubin, G.J. Psychological factors associated with reporting side effects following COVID-19 vaccination: A prospective cohort study (CoVAccS—Wave 3). J. Psychosom. Res. 2023, 164, 111104. [Google Scholar] [CrossRef]
- Barsky, A.J.; Saintfort, R.; Rogers, M.P.; Borus, J.F. Nonspecific Medication Side Effects and the Nocebo Phenomenon. JAMA 2002, 287, 622–627. [Google Scholar] [CrossRef]
- Faasse, K.; Petrie, K.J. The nocebo effect: Patient expectations and medication side effects. Postgrad. Med. J. 2013, 89, 540–546. [Google Scholar] [CrossRef][Green Version]
- Sever, P. Nocebo affects after COVID-19 vaccination. Lancet Reg. Health Eur. 2021, 12, 100273. [Google Scholar] [CrossRef]
- Amanzio, M.; Mitsikostas, D.D.; Giovannelli, F.; Bartoli, M.; Cipriani, G.E.; Brown, W.A. Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review. Lancet Reg. Health Eur. 2021, 12, 100253. [Google Scholar] [CrossRef]
- Lee, Y.H.; Song, G.G. Nocebo responses in randomized controlled trials of COVID-19 vaccines. Int. J. Clin. Pharmacol. Ther. 2022, 60, 5–12. [Google Scholar] [CrossRef] [PubMed]
- Webster, R.K.; Weinman, J.; Rubin, G.J. A systematic review of factors that contribute to nocebo effects. Health Psychol. 2016, 35, 1334–1355. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Vambheim, S.M.; Flaten, M.A. A systematic review of sex differences in the placebo and the nocebo effect. J. Pain Res. 2017, 10, 1831–1839. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Enck, P.; Klosterhalfen, S. Does Sex/Gender Play a Role in Placebo and Nocebo Effects? Conflicting Evidence From Clinical Trials and Experimental Studies. Front. Neurosci. 2019, 13, 160. [Google Scholar] [CrossRef]
- Hoffman, Y.S.G.; Levin, Y.; Palgi, Y.; Goodwin, R.; Ben-Ezra, M.; Greenblatt-Kimron, L. Vaccine hesitancy prospectively predicts nocebo side-effects following COVID-19 vaccination. Sci. Rep. 2022, 12, 20018. [Google Scholar] [CrossRef]
- Davies, H.T.; Crombie, I.K. Bias in cohort studies. Hosp. Med. 2000, 61, 133–135. Available online: http://www.ncbi.nlm.nih.gov/pubmed/10748794 (accessed on 9 March 2023).
- McCambridge, J.; Witton, J.; Elbourne, D.R. Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects. J. Clin. Epidemiol. 2014, 67, 267–277. [Google Scholar] [CrossRef][Green Version]
Figure 1.
The severity of side effects after each vaccine injection throughout the entire course of vaccination. a: Pfizer-BioNTech, n = 46 (64.8%), Sinopharm, n = 21 (29.6%), AstraZeneca, n = 4 (5.6%). b: Pfizer-BioNTech, n = 410 (55.3%), Sinopharm, n = 303 (40.9%), AstraZeneca, n = 28 (3.8%). c: Pfizer-BioNTech, n = 181 (70.4%), Sinopharm, n = 63 (24.5%), AstraZeneca, n = 13 (5.1%).
Figure 1.
The severity of side effects after each vaccine injection throughout the entire course of vaccination. a: Pfizer-BioNTech, n = 46 (64.8%), Sinopharm, n = 21 (29.6%), AstraZeneca, n = 4 (5.6%). b: Pfizer-BioNTech, n = 410 (55.3%), Sinopharm, n = 303 (40.9%), AstraZeneca, n = 28 (3.8%). c: Pfizer-BioNTech, n = 181 (70.4%), Sinopharm, n = 63 (24.5%), AstraZeneca, n = 13 (5.1%).
Table 1.
Characteristics of the participants.
| Variable | Outcome | Frequency (n = 1069) | Percentage (%) | |
|---|---|---|---|---|
| Gender | Male | 542 | 50.7% | |
| Female | 527 | 49.3% | ||
| Ag | <18 | 145 | 13.6% | |
| 18–40 | 681 | 63.7% | ||
| 40–60 | 179 | 16.7% | ||
| More 60 | 64 | 6% | ||
| Education | Primary School | 52 | 4.9% | |
| Secondary School | 179 | 16.7% | ||
| Diploma | 104 | 9.7% | ||
| Bachelor’s | 685 | 64.1% | ||
| Higher Education (Master/PhD) | 49 | 4.6% | ||
| Occupation | HCWs | 406 | 38% | |
| Non HCWs | 662 | 62% | ||
| Smoking | ||||
| Smoker | Yes | 195 | 18.2% | |
| No | 874 | 81.8% | ||
| Duration of Smoking (Years) | <5 | 85 | 43.6% | |
| 5–10 | 48 | 24.6% | ||
| >10 | 62 | 31.7% | ||
| Packets (Per day) | 1 | 153 | 78.4% | |
| 2 | 38 | 19.5% | ||
| 3 or more | 4 | 2% | ||
| Place of Residence | Amman | 701 | 65.6% | |
| Zarqa | 187 | 17.5% | ||
| Irbid | 35 | 3.3% | ||
| Mafraq | 34 | 3.2% | ||
| Balqa’ | 28 | 2.6% | ||
| Jerash | 25 | 2.3% | ||
| Madaba | 15 | 1.4% | ||
| Karak | 13 | 1.2% | ||
| Tafila | 12 | 1.1% | ||
| Ajloun | 9 | 0.8% | ||
| Ma’an | 5 | 0.5% | ||
| Aqaba | 5 | 0.5% | ||
| Vaccine type | Pfizer-Biontic | 637 | 59.6% | |
| Sinopharm | 387 | 36.2% | ||
| AstraZeneca | 45 | 4.2% | ||
| Number of doses | Single dose | 71 | 6.6% | |
| Two doses | 741 | 69.4% | ||
| Three doses | 257 | 24.0% | ||
| Vaccine type and doses | Pfizer-Biontic, n = 637 | Single dose | 46 | 7.2% |
| Two doses | 410 | 64.4% | ||
| Three doses | 181 | 28.4% | ||
| Sinopharm, n = 387 | Single dose | 21 | 5.4% | |
| Two doses | 303 | 78.3% | ||
| Three doses | 63 | 16.3% | ||
| AstraZeneca, n = 45 | Single dose | 4 | 8.9% | |
| Two doses | 28 | 62.2% | ||
| Three doses | 13 | 28.9% | ||
Table 2.
Allergies, Comorbidities, and Medications for individuals.
| Allergy | Yes | No | Not Sure | Total |
|---|---|---|---|---|
| Bee allergy | 34 | 881 | 154 | 1069 |
| Egg allergy | 19 | 1029 | 21 | 1069 |
| Fruit allergy | 6 | 1003 | 60 | 1069 |
| Milk allergy | 32 | 1005 | 32 | 1069 |
| Walnut allergy | 8 | 1037 | 24 | 1069 |
| Drug allergy | 59 | 897 | 113 | 1069 |
| Pet allergy | 72 | 932 | 65 | 1069 |
| Spring allergy | 270 | 728 | 71 | 1069 |
| Allergy to other things | 68 | 841 | 159 | 1068 |
| chronic disease | Yes | No | Not sure | Total |
| diabetes | 85 | 976 | 8 | 1069 |
| hypertension | 100 | 960 | 9 | 1069 |
| coronary artery disease | 64 | 995 | 10 | 1069 |
| liver disease | 8 | 1053 | 8 | 1069 |
| kidney disease | 9 | 1055 | 5 | 1069 |
| immunodeficiency | 10 | 1052 | 7 | 1069 |
| hematological disease | 15 | 1047 | 7 | 1069 |
| endocrine disease | 42 | 1016 | 11 | 1069 |
| respiratory disease | 41 | 1019 | 9 | 1069 |
| neurological disease | 8 | 1055 | 6 | 1069 |
| other diseases | 41 | 991 | 36 | 1068 |
| Medications | Yes | No | Not sure | Total |
| Hypertension medications | 103 | 963 | 3 | 1069 |
| Diabetes medications | 89 | 977 | 3 | 1069 |
| Anticoagulants | 95 | 971 | 3 | 1069 |
| Asthma medications | 37 | 1028 | 4 | 1069 |
| Thyroid hormone | 47 | 1016 | 6 | 1069 |
| Analgesics (NSAIDs, Paracetam) | 197 | 855 | 17 | 1069 |
| Opioids | 9 | 1056 | 4 | 1069 |
| Immunosuppressants | 22 | 1044 | 3 | 1069 |
| Antidepressants | 16 | 1048 | 5 | 1069 |
| Antibiotics | 65 | 997 | 7 | 1069 |
| Contraceptives | 20 | 1047 | 2 | 1069 |
| Seizure medications | 0 | 1067 | 2 | 1069 |
| Others | 74 | 983 | 11 | 1068 |
Table 3.
Side effects after each vaccine injection throughout the entire course of vaccination.
| One Dose (n = 71) a | Two Doses (n = 741) b | Three Doses, (n = 257) c | ||||
|---|---|---|---|---|---|---|
| Single Dose | 1st Shot | 2nd Shot | 1st Shot | 2nd Shot | 3rd Shot | |
| Ageusia | 0 (0%) | 22 (3%) | 37 (5%) | 3 (1%) | 3 (1%) | 13 (5%) |
| Anosmia | 2 (3%) | 30 (4%) | 44 (6%) | 5 (2%) | 23 (9%) | 13 (5%) |
| Arthralgia | 20 (28%) | 348 (47%) | 319 (43%) | 54 (21%) | 62 (24%) | 105 (41%) |
| Chest pain | 9 (13%) | 89 (12%) | 126 (17%) | 26 (10%) | 18 (7%) | 28 (11%) |
| Chills | 24 (34%) | 348 (47%) | 348 (47%) | 82 (32%) | 75 (29%) | 90 (35%) |
| Cough | 4 (6%) | 74 (10%) | 96 (13%) | 31 (12%) | 18 (7%) | 26 (10%) |
| Diarrhea | 6% (4) | 44 (6%) | 59 (8%) | 10 (4%) | 5 (2%) | 8 (3%) |
| dizziness | 11 (15%) | 177 (24%) | 185 (25%) | 41 (16%) | 15 (6%) | 59 (23%) |
| Face/lips swelling | 2 (3%) | 22 (3%) | 22 (3%) | 3 (1%) | 3 (1%) | 3 (1%) |
| Fatigue | 49 (69%) | 585 (79%) | 578 (78%) | 157 (61%) | 162 (63%) | 167 (65%) |
| Fever | 29 (41%) | 358 (52%) | 400 (54%) | 93 (36%) | 105 (41%) | 116 (45%) |
| Headache | 35 (49%) | 489 (66%) | 459 (62%) | 100 (39%) | 105 (41%) | 131 (51%) |
| localized pain | 53 (75%) | 615 (83%) | 585 (79%) | 200 (78%) | 167 (65%) | 195 (76%) |
| localized Redness | 24 (34%) | 259 (35%) | 274 (37%) | 113 (44%) | 89 (35%) | 105 (41%) |
| Myalgia | 27 (38%) | 437 (59%) | 393 (53%) | 64 (25%) | 67 (26%) | 115 (45%) |
| Nasal congestion | 13 (18%) | 89 (12%) | 104 (14%) | 31 (12%) | 21 (8%) | 33 (13%) |
| Nausea | 9 (13%) | 126 (17%) | 148 (20%) | 15 (6%) | 8 (3%) | 21 (8%) |
| Neurological symptoms | 0 (0%) | 22 (3%) | 30 (4%) | 3 (1%) | 5 (2%) | 23 (9%) |
| rhinorrhea | 13 (18%) | 82 (11%) | 104 (14%) | 31 (12%) | 23 (9%) | 39 (15%) |
| Shortness of breath | 16 (23%) | 126 (17%) | 163 (22%) | 28 (11%) | 15 (6%) | 26 (10%) |
| Sneezing | 6 (8%) | 67 (9%) | 93 (13%) | 21 (8%) | 13 (5%) | 28 (11%) |
| Sore throat | 11 (15%) | 96 (13%) | 89 (12%) | 26 (10%) | 21 (8%) | 51 (20%) |
| Vomiting | 6 (8%) | 30 (4%) | 37 (5%) | 5 (2%) | 3 (1%) | 15 (6%) |
a: Pfizer-BioNTech, n = 46 (64.8%), Sinopharm, n = 21 (29.6%), AstraZeneca, n = 4 (5.6%). b: Pfizer-BioNTech, n = 410 (55.3%), Sinopharm, n = 303 (40.9%), AstraZeneca, n = 28 (3.8%). c: Pfizer-BioNTech, n = 181 (70.4%), Sinopharm, n = 63 (24.5%), AstraZeneca, n = 13 (5.1%).
Table 4.
Comparison of onset and duration of side effects after each injection of vaccine throughout the entire course of vaccination.
Table 4.
Comparison of onset and duration of side effects after each injection of vaccine throughout the entire course of vaccination.
| Variables | One Dose (n = 71) a | Two Doses (n = 741) b | X2 (p-Value) d | Three Doses (n = 257) c | X2 (p-Value) e | |||
|---|---|---|---|---|---|---|---|---|
| Single Dose | 1st Shot | 2nd Shot | 1st Shot | 2nd Shot | 3rd Shot | |||
| The Onset of Side Effects after Vaccination | ||||||||
| within 24 h | 58 (82%) | 615 (83%) | 608 (82%) | 0.09 (0.76) | 231 (90%) | 221 (86%) | 244 (95%) | 8.1 (0.045) |
| 1–3 days | 13 (18%) | 111 (15%) | 111 (15%) | 0.17 (0.68) | 26 (10%) | 28 (11%) | 10 (4%) | 13.1 (0.0003) |
| 3–5 days | 0 (0%) | 7 (1%) | 7 (1%) | 0.19 (0.65) | 0 (0%) | 8 (3%) | 3 (1%) | 2.7 (0.12) |
| 1 week | 0 (0%) | 7 (1%) | 15 (2%) | 4.15 (0.042) | 0 (0%) | 0 (0%) | 0 (0%) | Not Applicable |
| Duration of side effects | ||||||||
| less than 24 h | 36 (51%) | 207 28%) | 81 (11%) | 104 (<0.0001) | 157 (61%) | 177 (69%) | 129 (50%) | 1.3 (0.25) |
| 1–3 days | 29 (41%) | 401 (54%) | 363 (49%) | 0.51 (0.48) | 44 (17%) | 59 (23%) | 33 (13%) | 13.9 (0.0002) |
| 3–7 days | 6 (8%) | 89 (12%) | 230 (31%) | 81.2 (<0.0001) | 44 (17%) | 18 (7%) | 59 (23%) | 6.1 (0.015) |
| more than 1 week | 0 (0%) | 44 (6%) | 67 (9%) | 10.5 (0.0012) | 12 (5%) | 3 (1%) | 36 (14%) | 24.1 (<0.0001) |
a: Pfizer-BioNTech, n = 46 (64.8%), Sinopharm, n = 21 (29.6%), AstraZeneca, n = 4 (5.6%). b: Pfizer-BioNTech, n = 410 (55.3%), Sinopharm, n = 303 (40.9%), AstraZeneca, n = 28 (3.8%). c: Pfizer-BioNTech, n = 181 (70.4%), Sinopharm, n = 63 (24.5%), AstraZeneca, n = 13 (5.1%). d: X2 The Chi-squared test (p-value) for single dose shot to multi shots in two doses. e: X2 The Chi-squared test (p-value) and for single dose shot to multi shots in three doses.
Table 5.
The frequency of reported side effects and their association with different variables after each vaccine injection throughout the entire course of vaccination.
Table 5.
The frequency of reported side effects and their association with different variables after each vaccine injection throughout the entire course of vaccination.
| One Dose (n = 71) | Two Doses (n = 741) | Three Doses (n = 257) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single Dose | 1st Shot | 2nd Shot | 1st Shot | 2nd Shot | 3rd Shot | ||||||||
| Variable | category | Reported Side Effects n (%) | P a (Phi Value) b | Reported Side Effects n (%) | P a (Phi Value) b | Reported Side Effects n (%) | P a (Phi Value) b | Reported Side Effects n (%) | P a (Phi Value)b | Reported Side Effects n (%) | P a (Phi Value) b | Reported Side Effects n (%) | P a (Phi Value) b |
| Gender | Female | 19 (59.4) | 0.15 | 204 (57.6) | 0.001, (0.53) | 160 (58) | 0.001, (0.38) | 77 (63.6) | 0.045 (0.13) | 59 (60.8) | 0.46 | 105 (60) | 0.29 |
| Male | 13 (40.6) | 150 (42.2) | 116 (42) | 44 (36.4) | 38 (39.2) | 70 (40) | |||||||
| Age | <18 | 14 (43.8) | 0.9 | 55 (15.5) | 0.9 | 56 (20.3) | 0.006 (0.11) | Not Applicable | |||||
| 18 -40 | 18 (56.3) | 299 (84.5) | 220 (79.7) | ||||||||||
| Smoker | No | 31 (96.9) | 0.35 | 311 (87.9) | 0.041, (0.08) | 244 (88.4) | 0.042 (0.08) | 84 (69.4) | 0.8 | 66 (68) | 0.75 | 121 (69.1) | 0.84 |
| Yes | 1 (3.1) | 43 (12.1) | 32 (11.6) | 37 (30.6) | 31 (32) | 54 (30.9) | |||||||
| Vaccine type | Pfizer | 22 (68.8) | 0.22 | 229 (64.7) | <0.001 (0.26) | 195 (70.7) | <0.001 (0.27) | 93 (76.9) | 0.002 (0.25) | 76 (78.4) | <0.001 (0.28) | 6 (3.4) | <0.001 (0.33) |
| Sinopharm | 7 (21.9) | 102 (28.8) | 67 (24.3) | 19 (15.7) | 15 (15.5) | 52 (29.7) | |||||||
| AstraZeneca | 3 (9.4) | 23 (6.5) | 14 (5.1) | 9 (7.4) | 6 (6.2) | 117 (66.9) | |||||||
a p-value for the chi-squared test (X2) for the association. Significant level <0.05. b Phi factor was illustrated in cases of significant p-value to demonstrate the strength of the association.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Odeh, M.; Al-Jussani, G.N.; Ashour, A.; AlNaqah, H.; Hasan, H.A.; Sbitan, L.; Dawabsheh, A.; Alhawi, M. Follow-Up of Side Effects throughout the Entire Course of Coronavirus Vaccination. Vaccines 2023, 11, 704. https://doi.org/10.3390/vaccines11030704
AMA Style
Odeh M, Al-Jussani GN, Ashour A, AlNaqah H, Hasan HA, Sbitan L, Dawabsheh A, Alhawi M. Follow-Up of Side Effects throughout the Entire Course of Coronavirus Vaccination. Vaccines. 2023; 11(3):704. https://doi.org/10.3390/vaccines11030704
Chicago/Turabian StyleOdeh, Mohanad, Ghada Nazar Al-Jussani, Abdelrahman Ashour, Husam AlNaqah, Hamza A. Hasan, Lana Sbitan, Amro Dawabsheh, and Moayad Alhawi. 2023. "Follow-Up of Side Effects throughout the Entire Course of Coronavirus Vaccination" Vaccines 11, no. 3: 704. https://doi.org/10.3390/vaccines11030704
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
